MIF098|cas:1208448-95-6|西域试剂

MIF098,99.84%

产品编号：Bellancom-147390| CAS NO：1208448-95-6| 分子式：C₁₅H₁₃NO₃| 分子量：255.27

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-147390	￥1500.00	杭州北京（现货）
Bellancom-147390	￥2500.00	杭州北京（现货）
Bellancom-147390	￥5500.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

MIF098

产品介绍

MIF098 是一种巨噬细胞迁移抑制因子 (MIF) 拮抗剂，可抑制肺平滑肌细胞增殖、迁移和纤维化。MIF098 可用于免疫炎症相关疾病研究。

生物活性

MIF098 is a macrophage migration inhibitory factor (MIF) antagonist. MIF098 inhibits proliferation, migration and fibrosis of pulmonary smooth muscle cells. MIF098 can be used for immunoinflammation-related disease research.

体外研究

MIF098 (0-10 μM, 48 h) inhibits mPASMC cell proliferation and migration in a concentration-dependent manner, by blocking the migration inhibitory factor (MIF) pathway.
MIF098 reduces collagen synthesis and pulmonary artery fibrosis by inhibiting the TGFβ1/Smad2/3 pathway.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis

Cell Line:	Mouse pulmonary artery smooth muscle cells (mPASMCs)
Concentration:	0-10 μM
Incubation Time:	48 hours
Result:	Reduced expression of cell cycle related proteins such as cyclin D1, CDK4 and CDK6 in PDGF-BB and increased expression of cell-cycle arrest proteins such as P53 and P21. Reduced TGFβ1-induced fibronectin (FN), collagen I (col I), and collagen II (col II) expression and phosphorylation of Smad2 and Smad3.

体内研究
(In Vivo)

MIF098 (intraperitoneal injection, 40 mg/kg, once a day, 4 weeks) attenuates the process of hypoxia-induced pulmonary arterial hypertension in C57BL/6J mice.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Hypoxic male C57BL/6J mice
Dosage:	40 mg/kg
Administration:	Intraperitoneal injection; once a day; 4 weeks
Result:	Reduced right ventricular systolic pressure (RVSP), percentage medial wall thickness, muscularization and right ventricle collagen deposition. Decreased percentage of collagen fibers in pulmonary artery (PA).

体内研究

MIF098 (intraperitoneal injection, 40 mg/kg, once a day, 4 weeks) attenuates the process of hypoxia-induced pulmonary arterial hypertension in C57BL/6J mice.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Hypoxic male C57BL/6J mice
Dosage:	40 mg/kg
Administration:	Intraperitoneal injection; once a day; 4 weeks
Result:	Reduced right ventricular systolic pressure (RVSP), percentage medial wall thickness, muscularization and right ventricle collagen deposition. Decreased percentage of collagen fibers in pulmonary artery (PA).

体内研究

MIF098 (intraperitoneal injection, 40 mg/kg, once a day, 4 weeks) attenuates the process of hypoxia-induced pulmonary arterial hypertension in C57BL/6J mice.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Hypoxic male C57BL/6J mice
Dosage:	40 mg/kg
Administration:	Intraperitoneal injection; once a day; 4 weeks
Result:	Reduced right ventricular systolic pressure (RVSP), percentage medial wall thickness, muscularization and right ventricle collagen deposition. Decreased percentage of collagen fibers in pulmonary artery (PA).

性状

Solid

溶解性数据

In Vitro:

DMSO : 180 mg/mL (705.14 mM; ultrasonic and warming and heat to 60°C)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	3.9174 mL	19.5871 mL	39.1742 mL
5 mM	0.7835 mL	3.9174 mL	7.8348 mL
10 mM	0.3917 mL	1.9587 mL	3.9174 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (stored under nitrogen)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: ≥ 5 mg/mL (19.59 mM); Clear solution

此方案可获得 ≥ 5 mg/mL (19.59 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 50.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液
2.

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in saline)
Solubility: 5 mg/mL (19.59 mM); Suspended solution; Need ultrasonic

此方案可获得 5 mg/mL (19.59 mM) 的均匀悬浊液，悬浊液可用于口服和腹腔注射。
以 1 mL 工作液为例，取 100 μL 50.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
3.

请依序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: ≥ 5 mg/mL (19.59 mM); Clear solution

此方案可获得 ≥ 5 mg/mL (19.59 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。
以 1 mL 工作液为例，取 100 μL 50.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。